*Cette information spécialisée n’est disponible qu’en anglais conformément au Règlement de l’Ontario 671/92. Pour toute question, veuillez envoyer un courriel à [email protected].
The following are the decisions for drugs considered by our drug advisory committee for inclusion to our formularies:
- Aripiprazole
- Benzodiazepines
- Botulinum Toxin A: Botox®,Botox Cosmetic®, Xeomin®
- Buprenorphine (Opioid use disorder)
- Buprenorphine (Treatment of chronic pain)
- Calcitonin Gene-Related Peptide Monoclonal Antibodies in prevention of migraine
- Cannabinoid: Nabilone
- Compounded Topical Analgesics
- Corticosteroid injections (musculoskeletal conditions)*
- Desvenlafaxine
- Diclofenac Sodium Solution 1.5%
- Duloxetine
- Escitalopram
- HIV Post-Exposure Prophylaxis
- Hypnotics: Zopiclone, Trazodone and Tryptophan
- Ketamine and esketamine
- Oxycodone/Naloxone Controlled Release
- Paliperidone
- Piroxicam
- Pregabalin
- Repetitive transcranial magnetic stimulation for treatment-resistant depression
- Skeletal Muscle Relaxants
- Spinal cord stimulator
- Tapentadol Controlled Release
- Tramadol
- Viscosupplements
- Ziprasidone
Updated: